Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)

Table 1 Baseline characteristics

Variables	Analysis for
Variables	Efficacy (N = 24)	Safety (N = 30)
Age (years)	75.5 ± 6.9	76.2 ± 7.3
Female sex (n)	12	15
Height (cm)	155.2 ± 8.7	154.9 ± 9.1
Body weight (kg)	57.4 ± 11.5	56.4 ± 10.8
BMI (kg/m²)	23.7 ± 3.4	23.4 ± 3.1
Diabetes duration (years)^a	17.0 [7.0, 23.0]	17.0 [9.5, 24.0]
FPG (mmol/L)^a	7.7 ± 2.0	8.1 ± 2.2
HbA1c (mmol/mol)	63.1 ± 8.5	63.6 ± 8.0
CPR (nmol/L)^a	0.6 ± 0.3	0.6 ± 0.3
CPI (ng/mL per mg/dL)^a	1.5 ± 0.8	1.4 ± 0.8
Evaluation for cognitive function
DASC-8	8.5 [8.0, 9.0]	9.0 [8.0, 9.0]
HDS-R	25.6 ± 3.8	25.4 ± 4.2
The proportion of anti-diabetic agent (n, %)
The number of drugs	2.0 [2.0, 3.0]	2.0 [2.0, 3.0]
Biguanide	12 (50.0)	13 (43.3)
DPP-4i	22 (91.7)	28 (93.3)
SU	6 (25.0)	8 (26.7)
Glinides	4 (16.7)	5 (16.7)
Thiazolidine	1 (4.2)	1 (3.3)
α-GI	1 (4.2)	3 (10.0)
SGLT2i	11 (45.8)	14 (46.7)
Insulin	2 (8.3)	3 (10.0)

Values are expressed as mean ± SD or median (interquartile range). Data are shown for 24 subjects in an efficacy analysis and 30 subjects in a safety analysis
BMI Body mass index, CPI C-peptide index, CPR C-peptide, DASC-8 Dementia assessment sheet for community-based integrated care system 8-items, DPP-4i Dipeptidyl peptidase-4 inhibitor, FPG Fasting plasma glucose, HbA1c Glycated hemoglobin, HDS-R Hasegawa dementia rating scale-revised, SGLT2i Sodium-glucose cotransporter 2 inhibitor, SU Sulfonylurea
^aThe values were calculated except one subject for missing data. α-GI, alpha glucosidase inhibitors

ISSN: 1472-6823